Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior t... by Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff

Get full text

Clinical, therapeutic and prognostic differences between male and female patients with breast cancer—a comparison of 2510 men and 307,634 women in a registry-based study in Germany... by Marion Graf, Michael Gerken, Monika Klinkhammer-Schalke, Simone Schrodi, Armin Pauer, Karla Geiss, Olaf Ortmann, Elisabeth C. Sturm-Inwald

Get full text

Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy by Verena Schweihofer, Christina Bruss, Stephan Seitz, Gunther Glehr, Madeleine Hetterich, Florian Weber, Maria Hatzipanagiotou, Miriam Fernández-Pacheco Álvarez, Olaf Ortmann, Gero Brockhoff, Richard J. Bauer, Anja Kathrin Wege

Get full text

Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification by Kristin Galas, Moritz Gleitsmann, Julia Rey, Christine Solbach, Isabell Witzel, Thomas Karn, Sabine Schmatloch, Christian Schem, Andreas Schneeweis, Bruno Sinn, Tanja Fehm, Carsten Denkert, Peter Fasching, Anne-Sophie Litmeyer, Frederik Marmé, Paul Jank, Volkmar Müller, Sabine Seiler, Elmar Stickeler, Olaf Ortmann, Marion van Mackelenbergh, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl

Get full text